Werewolf Therapeutics Updates Executive Compensation Arrangements

Ticker: HOWL · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1785530

Werewolf Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyWerewolf Therapeutics, Inc. (HOWL)
Form Type8-K
Filed DateJan 4, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001, $40,000, $4,000, $5
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: compensatory-arrangements, executive-compensation, corporate-governance

TL;DR

**Werewolf Therapeutics just updated executive pay, watch for impact on talent and financials.**

AI Summary

Werewolf Therapeutics, Inc. filed an 8-K on January 4, 2024, to report changes in its executive compensation arrangements. This filing, under Item 5.02, indicates adjustments to compensatory plans for certain officers, which could impact the company's operational costs and executive incentives. For investors, understanding these changes is crucial as they can influence executive retention, motivation, and ultimately, the company's financial performance and stock value.

Why It Matters

Changes in executive compensation can affect a company's financial health and its ability to attract and retain top talent, directly influencing investor confidence and stock performance.

Risk Assessment

Risk Level: low — This filing primarily concerns routine executive compensation arrangements, which typically carry a low direct risk unless they involve unusually large or controversial payouts.

Analyst Insight

A smart investor would monitor subsequent filings or press releases for specific details regarding the new compensatory arrangements to assess their potential impact on the company's financials and executive stability.

Key Players & Entities

  • Werewolf Therapeutics, Inc. (company) — the registrant filing the 8-K
  • January 4, 2024 (date) — date of earliest event reported and filing date
  • 001-40366 (other) — Commission File Number
  • HOWL (other) — Trading Symbol for Common Stock
  • The Nasdaq Global Select Market (other) — exchange where Common Stock is registered

FAQ

What is the primary purpose of this 8-K filing by Werewolf Therapeutics, Inc.?

The primary purpose of this 8-K filing, dated January 4, 2024, is to report on 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' under Item 5.02.

What is the trading symbol and exchange for Werewolf Therapeutics, Inc.'s common stock?

Werewolf Therapeutics, Inc.'s common stock trades under the symbol HOWL on The Nasdaq Global Select Market.

What is the business address of Werewolf Therapeutics, Inc. as stated in the filing?

The business address of Werewolf Therapeutics, Inc. is 200 Talcott Ave, 2nd Floor, Watertown, Massachusetts, 02472.

What is the company's telephone number?

The registrant's telephone number, including area code, is (617) 952-0555.

Under which SEC Act is this 8-K filed?

This 8-K is filed under the Securities Exchange Act of 1934.

Filing Stats: 914 words · 4 min read · ~3 pages · Grade level 11.9 · Accepted 2024-01-04 17:00:01

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share HOWL The Nasdaq
  • $40,000 — ill receive annual cash compensation of $40,000 for service as a director and $4,000 fo
  • $4,000 — f $40,000 for service as a director and $4,000 for service as a member of the Nominati
  • $5 — common stock, with an exercise price of $5.25, equal to the closing price of the C

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WEREWOLF THERAPEUTICS, INC. Date: January 4, 2023 By: /s/ Timothy W. Trost Timothy W. Trost Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.